AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34700768 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific treatment planning using numerical simulations
Number of subjects: 1
Study 34984636 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid coverage
Number of subjects: 0
Study 34984636 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Medicaid coverage)
Number of subjects: 0
Study 34154034 — intervention group
Group type: EXPERIMENTAL
Intervention: GLE/PIB without ribavirin
Number of subjects: 32
Study 34154034 — intervention group
Group type: EXPERIMENTAL
Intervention: GLE/PIB with ribavirin
Number of subjects: 32
Study 34154034 — intervention group
Group type: COMPARATOR
Intervention: Treatment failure patients
Number of subjects: 32
Study 34154034 — intervention group
Group type: COMPARATOR
Intervention: SVR12 achievers
Number of subjects: 32
Study 34154034 — intervention group
Group type: COMPARATOR
Intervention: Retreatment with sofosbuvir-based regimens
Number of subjects: 32
Study 32299254 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 156
Study 32299254 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (50 mg)
Number of subjects: 156
Study 32299254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 36098201 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ppm chitosan nanoparticles
Number of subjects: 10
Study 36098201 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ppm silica nanoparticles
Number of subjects: 10
Study 34138638 — intervention group
Group type: EXPERIMENTAL
Intervention: Imetelstat 9.4 mg/kg
Number of subjects: 0
Study 34138638 — intervention group
Group type: COMPARATOR
Intervention: Imetelstat 4.7 mg/kg
Number of subjects: 0
Study 32304590 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35718440 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% curcumin nanomicelle gel
Number of subjects: 48
Study 35718440 — intervention group
Group type: COMPARATOR
Intervention: 2% curcumin gel
Number of subjects: 48
Study 34607863 — intervention group
Group type: EXPERIMENTAL
Intervention: Online chronic disease self-management programme (CDSMP) plus medication adherence tools
Number of subjects: 24
Study 34607863 — intervention group
Group type: COMPARATOR
Intervention: Didactic lecture only
Number of subjects: 24
Study 32756146 — intervention group
Group type: EXPERIMENTAL
Intervention: New method group (group A)
Number of subjects: 200
Study 32756146 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 200
Study 35322981 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline (5 mL)
Number of subjects: 42
Study 35322981 — intervention group
Group type: COMPARATOR
Intervention: Contrast medium (5 mL)
Number of subjects: 42
Study 36449375 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous fully closed-loop (FCL; CamAPS HX) insulin therapy
Number of subjects: 0
Study 36449375 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) insulin therapy
Number of subjects: 0
Study 36449375 — intervention group
Group type: COMPARATOR
Intervention: Comparison of FCL vs UC
Number of subjects: 0
Study 33719017 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal glulisine 20 IU twice daily
Number of subjects: 35
Study 33719017 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 35
Study 32612186 — intervention group
Group type: EXPERIMENTAL
Intervention: Avocado pulp (600 mg in capsule)
Number of subjects: 16
Study 32612186 — intervention group
Group type: COMPARATOR
Intervention: Placebo (600 mg starch in capsule)
Number of subjects: 16
Study 32804855 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 µg CrPic tablets (200 µg in two divided doses) daily for 12 weeks
Number of subjects: 46
Study 32804855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 33151727 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional forced-choice (MFC) format
Number of subjects: 1867
Study 33151727 — intervention group
Group type: COMPARATOR
Intervention: Rating scale (RS) format
Number of subjects: 1867
Study 33151727 — intervention group
Group type: EXPERIMENTAL
Intervention: MFC format with mixed triplets
Number of subjects: 1867
Study 33151727 — intervention group
Group type: EXPERIMENTAL
Intervention: MFC format with fully matched triplets
Number of subjects: 1867
Study 32087795 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide 25 mg once a day
Number of subjects: 490
Study 32087795 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate 300 mg once a day
Number of subjects: 490
Study 32521121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinematic Rendering (CR)
Number of subjects: 16
Study 32521121 — intervention group
Group type: COMPARATOR
Intervention: Conventional Computed Tomography (CT)
Number of subjects: 16
Study 34904748 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA)
Number of subjects: 32
Study 34904748 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic plasma exchange (TPE)
Number of subjects: 32
Study 34009313 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MINT) sessions for 3 months
Number of subjects: 355
Study 34009313 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 355
Study 32080858 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured gingival fibroblasts (GF) on β‐calcium triphosphate (β‐TCP) scaffold covered by a collagen membrane.
Number of subjects: 20
Study 32080858 — intervention group
Group type: COMPARATOR
Intervention: β‐calcium triphosphate (β‐TCP) followed by collagen membrane defect coverage.
Number of subjects: 20
Study 32080858 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured gingival fibroblasts (GF) on β‐TCP scaffold.
Number of subjects: 20
Study 36578750 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin matrix (PRFM) procedure done every 2 weeks with maximum three sittings
Number of subjects: 41
Study 36578750 — intervention group
Group type: COMPARATOR
Intervention: Transplantation of autologous noncultured epidermal cell suspension (NCES) procedure done once
Number of subjects: 41
Study 34648075 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb remote ischaemic conditioning (RIC)
Number of subjects: 169
Study 34648075 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 169
Study 34648075 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb remote ischaemic conditioning (RIC) in anterior STEMI subgroup
Number of subjects: 169
Study 34648075 — intervention group
Group type: COMPARATOR
Intervention: Control in anterior STEMI subgroup
Number of subjects: 169
Study 35843050 — intervention group
Group type: EXPERIMENTAL
Intervention: Inorganic nitrate intake (10 mmol potassium nitrate)
Number of subjects: 18
Study 35843050 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (isomolar potassium chloride)
Number of subjects: 18
Study 35843050 — intervention group
Group type: EXPERIMENTAL
Intervention: Inorganic nitrate intake
Number of subjects: 18
Study 33406944 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFETY program
Number of subjects: 0
Study 33602890 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous reperfusion (SIM)
Number of subjects: 61
Study 33602890 — intervention group
Group type: COMPARATOR
Intervention: Primary portal vein reperfusion (PV)
Number of subjects: 61
Study 33602890 — intervention group
Group type: COMPARATOR
Intervention: Primary arterial reperfusion (A)
Number of subjects: 61
Study 33065990 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive intervention
Number of subjects: 2294
Study 33065990 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2294
Study 35680097 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant intravitreal therapy with 200 mg/ml 5-Fluorouracil (5-FU) and 5 IU/ml dalteparin (low-molecular weight heparin)
Number of subjects: 325
Study 35680097 — intervention group
Group type: COMPARATOR
Intervention: Placebo (balanced salt solution)
Number of subjects: 325
Study 35680097 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant intravitreal therapy with 5-FU and LMWH
Number of subjects: 325
Study 34710343 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl 4 g daily
Number of subjects: 1837
Study 34710343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1837
Study 32794478 — intervention group
Group type: EXPERIMENTAL
Intervention: Thumb spica cast with methylprednisolone acetate and xylocaine injection
Number of subjects: 134
Study 32794478 — intervention group
Group type: COMPARATOR
Intervention: Thumb spica cast alone
Number of subjects: 134
Study 33503393 — intervention group
Group type: EXPERIMENTAL
Intervention: Encorafenib plus Cetuximab plus Binimetinib (triplet)
Number of subjects: 665
Study 33503393 — intervention group
Group type: EXPERIMENTAL
Intervention: Encorafenib plus Cetuximab (doublet)
Number of subjects: 665
Study 33503393 — intervention group
Group type: COMPARATOR
Intervention: Control (irinotecan or FOLFIRI plus cetuximab)
Number of subjects: 665
Study 32000772 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 1061
Study 32000772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1061
Study 35189911 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet group
Number of subjects: 28
Study 35189911 — intervention group
Group type: COMPARATOR
Intervention: Non-tourniquet group
Number of subjects: 28
Study 33141923 — intervention group
Group type: EXPERIMENTAL
Intervention: Firsocostat (FIR) 10 mg
Number of subjects: 28
Study 33141923 — intervention group
Group type: EXPERIMENTAL
Intervention: Firsocostat (FIR) 10 mg plus rifampin (RIF) 300 mg i.v.
Number of subjects: 28
Study 33141923 — intervention group
Group type: COMPARATOR
Intervention: Rifampin (RIF) 300 mg i.v. (control)
Number of subjects: 28
Study 35619144 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted closure (VAC)
Number of subjects: 340
Study 35619144 — intervention group
Group type: COMPARATOR
Intervention: Primary closure with relaparotomy on-demand (ROD)
Number of subjects: 340
Study 35619144 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC
Number of subjects: 340
Study 35619144 — intervention group
Group type: COMPARATOR
Intervention: ROD
Number of subjects: 340
Study 34047372 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose genistein aglycone (160 mg/kg/day)
Number of subjects: 21
Study 34047372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 36077269 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythritol (10g, 25g, 50g)
Number of subjects: 17
Study 36077269 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol (7g, 17g, 35g)
Number of subjects: 17
Study 33946072 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided cognitive-behavioral web-based intervention (WBI) + treatment as usual (TAU)
Number of subjects: 136
Study 33946072 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 136
Study 34301165 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised resistance training (EXE, n = 9)
Number of subjects: 17
Study 34301165 — intervention group
Group type: COMPARATOR
Intervention: Home-based stretching (STRETCH, n = 8)
Number of subjects: 17
Study 33063780 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable; no specific intervention mentioned.
Number of subjects: 0
Study 32597672 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with personalized corrective feedback
Number of subjects: 492
Study 32597672 — intervention group
Group type: COMPARATOR
Intervention: Viewing and rating faces without feedback
Number of subjects: 492
Study 33648819 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive brain stimulation combined with sensorimotor training
Number of subjects: 98
Study 32304001 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical conventional treatment and diode laser application with wavelength of 980 nm (TG)
Number of subjects: 23
Study 32304001 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical conventional treatment (CG)
Number of subjects: 23
Study 34647482 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult day services continued during the pandemic (telephone support, food delivery, medical check-ins, activities via Zoom/YouTube)
Number of subjects: 22
Study 34647482 — intervention group
Group type: COMPARATOR
Intervention: Closure of adult day services due to COVID-19
Number of subjects: 22
Study 34647482 — intervention group
Group type: EXPERIMENTAL
Intervention: Staffing changes due to COVID-19
Number of subjects: 22
Study 35818840 — intervention group
Group type: COMPARATOR
Intervention: QI coaching
Number of subjects: 267
Study 35818840 — intervention group
Group type: COMPARATOR
Intervention: Combined intervention (QI coaching + remote provider communication training)
Number of subjects: 267
Study 35818840 — intervention group
Group type: COMPARATOR
Intervention: Remote communication training
Number of subjects: 267
Study 33783390 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized capillary blood sampling protocol, staff education, randomized audits of heel-stick technique
Number of subjects: 0
Study 32278939 — intervention group
Group type: EXPERIMENTAL
Intervention: Detour message only on the VMS
Number of subjects: 39
Study 32278939 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrelevant VMS messages before the detour message
Number of subjects: 39
Study 32278939 — intervention group
Group type: EXPERIMENTAL
Intervention: Inconsistent detour message with destination
Number of subjects: 39
Study 32278939 — intervention group
Group type: COMPARATOR
Intervention: Control group (detour message only)
Number of subjects: 39
Study 33438442 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine with EPA-enriched oral supplement (1,000 mg/m2 gemcitabine on days 1, 8, and 15 every 4 weeks; EPA 1.056 mg per pack, maximum of two packs daily)
Number of subjects: 68
Study 33438442 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine monotherapy (1,000 mg/m2 on days 1, 8, and 15 every 4 weeks)
Number of subjects: 68
Study 33526709 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg SC every 2 weeks (q2w)
Number of subjects: 1820
Study 33526709 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg SC every 4 weeks (q4w)
Number of subjects: 1820
Study 33526709 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sirukumab dosages
Number of subjects: 1820
Study 32267366 — intervention group
Group type: EXPERIMENTAL
Intervention: General obesity (BMI percentile ≥ 85)
Number of subjects: 486
Study 32267366 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal obesity (WC percentile > 90)
Number of subjects: 486
Study 32267366 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI percentile as a continuous variable
Number of subjects: 486
Study 32267366 — intervention group
Group type: EXPERIMENTAL
Intervention: WC percentile as a continuous variable
Number of subjects: 486
Study 35334418 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (n = 824)
Number of subjects: 3420
Study 35334418 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic statins (n = 87)
Number of subjects: 3420
Study 35334418 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic statins in the denosumab arm
Number of subjects: 3420
Study 35334418 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipophilic statins (n = 710)
Number of subjects: 3420
Study 35334418 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 3420
Study 34630613 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Shenlu granule (SLG) supportive group (group A, n = 44)
Number of subjects: 89
Study 34630613 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B, n = 45)
Number of subjects: 89
Study 32933356 — intervention group
Group type: EXPERIMENTAL
Intervention: myo-inositol supplementation (2000 mg of myo-inositol and 200 μg of folic acid)
Number of subjects: 60
Study 33043688 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP initiation and re-supply
Number of subjects: 19
Study 33043688 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer adherence support
Number of subjects: 19
Study 35653577 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac 30 mg
Number of subjects: 124
Study 35653577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 34087482 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-tDCS (high-definition transcranial direct current stimulation)
Number of subjects: 50
Study 34087482 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 50
Study 33377611 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab monthly regimen (0.5 mg) from baseline to Month 11
Number of subjects: 334
Study 33377611 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab PRN regimen (0.5 mg) from Month 12 to Month 23
Number of subjects: 334
Study 32232968 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed preservatives group
Number of subjects: 12454
Study 32232968 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% preservatives group
Number of subjects: 12454
Study 32232968 — intervention group
Group type: COMPARATOR
Intervention: 0% preservatives group
Number of subjects: 12454
Study 35321000 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow oxygen therapy
Number of subjects: 140
Study 35321000 — intervention group
Group type: COMPARATOR
Intervention: General oxygen therapy
Number of subjects: 140
Study 32043344 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution (CES)
Number of subjects: 23
Study 32043344 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte-protein solution (CEPS)
Number of subjects: 23
Study 32043344 — intervention group
Group type: COMPARATOR
Intervention: Comparison between CES and CEPS
Number of subjects: 23
Study 35848336 — intervention group
Group type: EXPERIMENTAL
Intervention: OCS‐01 (dexamethasone ophthalmic suspension), 1 drop 3 times/day for 12 weeks
Number of subjects: 144
Study 35848336 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (matching vehicle), 1 drop 3 times/day for 12 weeks
Number of subjects: 144
Study 35848336 — intervention group
Group type: EXPERIMENTAL
Intervention: OCS‐01 (dexamethasone ophthalmic suspension)
Number of subjects: 144
Study 35848336 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (matching vehicle)
Number of subjects: 144
Study 32944843 — intervention group
Group type: EXPERIMENTAL
Intervention: GMB 120 mg
Number of subjects: 270
Study 32944843 — intervention group
Group type: EXPERIMENTAL
Intervention: GMB 240 mg
Number of subjects: 270
Study 35313932 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly medical staff knowledge assessments using interactive vignettes with financial bonus payments for performance.
Number of subjects: 110
Study 35313932 — intervention group
Group type: COMPARATOR
Intervention: Control group (no financial incentives or knowledge assessments).
Number of subjects: 110
Study 33243380 — intervention group
Group type: EXPERIMENTAL
Intervention: TMVr with the MitraClip plus guideline-directed medical therapy (GDMT) (n = 302)
Number of subjects: 614
Study 33243380 — intervention group
Group type: COMPARATOR
Intervention: GDMT alone (n = 312)
Number of subjects: 614
Study 33243380 — intervention group
Group type: EXPERIMENTAL
Intervention: TMVr with the MitraClip
Number of subjects: 614
Study 34169381 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC) administered daily for up to 15 days
Number of subjects: 55
Study 34169381 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC)
Number of subjects: 55
Study 35523505 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-nutrient supplement (330 kcal, 20 g protein, 1.5 g calcium 3-hydroxy-3-methylbutyrate monohydrate, 449 mg calcium, 500 IU vitamin D3, and 25 vitamins and minerals)
Number of subjects: 160
Study 35523505 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-nutrient supplement
Number of subjects: 160
Study 35523505 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 160
Study 33466190 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing
Number of subjects: 0
Study 33466190 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane foam dressing
Number of subjects: 0
Study 33563049 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acupuncture and medical training therapy
Number of subjects: 95
Study 33563049 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 95
Study 33563049 — intervention group
Group type: EXPERIMENTAL
Intervention: All intervention groups (including acupuncture and medical training therapy)
Number of subjects: 95
Study 32574352 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia challenge test (HCT) in T1D group
Number of subjects: 24
Study 32574352 — intervention group
Group type: COMPARATOR
Intervention: Hypoxia challenge test (HCT) in control group
Number of subjects: 24
Study 32574352 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip test in T1D group
Number of subjects: 24
Study 32574352 — intervention group
Group type: COMPARATOR
Intervention: Handgrip test in control group
Number of subjects: 24
Study 34224510 — intervention group
Group type: EXPERIMENTAL
Intervention: PO TXA (1.95 g 2 hours preoperatively)
Number of subjects: 261
Study 34224510 — intervention group
Group type: COMPARATOR
Intervention: IV TXA (2 g: 1 g before incision and 1 g before wound closure)
Number of subjects: 261
Study 34769944 — intervention group
Group type: EXPERIMENTAL
Intervention: Swim for Safety educational programme (12 lessons, face-to-face)
Number of subjects: 156
Study 34769944 — intervention group
Group type: COMPARATOR
Intervention: Control group (brochure and weekly mobile phone messages for six weeks)
Number of subjects: 156
Study 32664090 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid sodium phosphocreatine cardiac arrest
Number of subjects: 84
Study 32664090 — intervention group
Group type: COMPARATOR
Intervention: Conventional modified St Thomas II high potassium cold liquid crystal cardiac arrest
Number of subjects: 84
Study 34740099 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRE)
Number of subjects: 44
Study 34740099 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 44
Study 33049708 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐mobilization (Self‐Mob)
Number of subjects: 18